NYSE:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis → AI's Next Magnificent Seven (From The Oxford Club) (Ad) Free CATX Stock Alerts $9.97 +0.10 (+1.01%) (As of 06/28/2024 08:56 PM ET) Add Compare Share Share Today's Range$9.49▼$10.1550-Day Range N/A52-Week Range$2.05▼$19.05Volume7.95 million shsAverage Volume584,690 shsMarket Capitalization$620.76 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Perspective Therapeutics alerts: Email Address Perspective Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside90.6% Upside$19.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 3 Articles This WeekInsider TradingAcquiring Shares$385,487 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.01) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.55 out of 5 starsMedical Sector469th out of 916 stocksSurgical & Medical Instruments Industry56th out of 97 stocks 4.5 Analyst's Opinion Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePerspective Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Perspective Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CATX. Previous Next 0.0 Dividend Strength Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CATX. Previous Next 1.8 News and Social Media Coverage News SentimentPerspective Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Perspective Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $385,487.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.52% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from ($1.01) to ($1.13) per share.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” Please, watch this now before it’s too late. About Perspective TherapeuticsPerspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Read More CATX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CATX Stock News HeadlinesJune 19, 2024 | insidertrades.comPerspective Therapeutics, Inc. (NYSE:CATX) CFO Jonathan Robert Hunt Acquires 1,800 SharesJune 14, 2024 | insidertrades.comPerspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor Acquires 100,000 SharesJuly 1, 2024 | Porter & Company (Ad)Trump’s arrest is phase oneIn this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election… June 5, 2024 | insidertrades.comLori A. Woods Buys 34,246 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockJune 4, 2024 | insidertrades.comInsider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) CFO Purchases 25,006 Shares of StockJune 27, 2024 | americanbankingnews.comPerspective Therapeutics (NYSE:CATX) Stock Rating Reaffirmed by Cantor FitzgeraldJune 12, 2024 | globenewswire.comPerspective Therapeutics Announces Inclusion in the Russell 3000® IndexJune 11, 2024 | globenewswire.comPerspective Therapeutics Announces 1-for-10 Reverse Stock SplitJuly 1, 2024 | Porter & Company (Ad)Trump’s arrest is phase oneIn this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election… June 10, 2024 | globenewswire.comPerspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingMay 27, 2024 | seekingalpha.comPerspective Therapeutics: An Elevated Theranostics Play Flying Under Your RadarMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Perspective Therapeutics Amid Promising Competitor Data and Treatment InnovationsMay 24, 2024 | globenewswire.comPerspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsMay 20, 2024 | globenewswire.comPerspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024May 17, 2024 | bizjournals.comGT Medical Technologies acquires cancer treatment subsidiary from Seattle companyMay 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)May 15, 2024 | bizjournals.comPerspective Therapeutics sells subsidiary to Arizona companyMay 15, 2024 | investorplace.comCATX Stock Earnings: Perspective Therapeutics Meets EPS for Q1 2024May 15, 2024 | washingtonpost.comPerspective Therapeutics: Q1 Earnings SnapshotMay 15, 2024 | globenewswire.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 ResultsMay 14, 2024 | msn.comRBC Capital Initiates Coverage of Perspective Therapeutics (CATX) with Outperform RecommendationMay 9, 2024 | msn.comCantor Fitzgerald Initiates Coverage of Perspective Therapeutics (CATX) with Overweight RecommendationMay 3, 2024 | globenewswire.comPerspective Therapeutics to Participate at Upcoming May Investor ConferencesMay 2, 2024 | markets.businessinsider.comThe Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 ExpertsMay 2, 2024 | finance.yahoo.comPerspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comPerspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial ResultsApril 30, 2024 | globenewswire.comPerspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETsSee More Headlines Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:CATX CUSIPN/A CIK728387 Webwww.perspectivetherapeutics.com Phone206-676-0900Fax509-267-3670Employees116Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$30.00 Low Stock Price Target$14.00 Potential Upside/Downside+90.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,510,000.00 Net Margins-302.70% Pretax Margin-3,379.88% Return on Equity-46.38% Return on Assets-39.17% Debt Debt-to-Equity Ratio0.01 Current Ratio12.98 Quick Ratio12.98 Sales & Book Value Annual Sales$1.43 million Price / Sales434.10 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book3.73Miscellaneous Outstanding Shares62,263,000Free Float60,071,000Market Cap$620.76 million OptionableN/A Beta1.42 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Johan M. Spoor (Age 52)CEO & Director Comp: $855.78kMr. Jonathan R. Hunt (Age 57)CFO & Co-Principal Financial Officer Comp: $944.35kDr. Markus Puhlmann M.B.A. (Age 58)M.D., Chief Medical Officer Comp: $633.14kMr. Shane CobbExecutive Vice President of OperationsMr. Mark J. Austin CPA (Age 37)VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary Dr. Michael K. Schultz Ph.D.Chief Science OfficerMr. Andrew BrightExecutive Vice President of BrachytherapyMr. Amos Hedt BAPGradDip, Chief Business Strategy OfficerDr. Frances L. Johnson M.D.Chief Innovation OfficerMr. David Hauser Ph.D.Senior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsIntegra LifeSciencesNASDAQ:IARTUFP TechnologiesNASDAQ:UFPTLeMaitre VascularNASDAQ:LMATNovoCureNASDAQ:NVCRAlphatecNASDAQ:ATECView All CompetitorsInsiders & InstitutionsJonathan Robert HuntBought 1,800 shares on 6/17/2024Total: $17,658.00 ($9.81/share)Lori A WoodsBought 4,587 shares on 6/14/2024Total: $49,998.30 ($10.90/share)Johan M SpoorBought 10,000 shares on 6/13/2024Total: $117,000.00 ($11.70/share)Lori A WoodsBought 3,424 shares on 6/3/2024Total: $49,990.40 ($14.60/share)Robert F Williamson IIIBought 5,500 shares on 5/31/2024Total: $75,900.00 ($13.80/share)View All Insider TransactionsView All Institutional Transactions CATX Stock Analysis - Frequently Asked Questions Should I buy or sell Perspective Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Perspective Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CATX shares. View CATX analyst ratings or view top-rated stocks. What is Perspective Therapeutics' stock price target for 2024? 6 brokers have issued 1 year price targets for Perspective Therapeutics' stock. Their CATX share price targets range from $14.00 to $30.00. On average, they expect the company's stock price to reach $19.00 in the next year. This suggests a possible upside of 90.6% from the stock's current price. View analysts price targets for CATX or view top-rated stocks among Wall Street analysts. How have CATX shares performed in 2024? Perspective Therapeutics' stock was trading at $11.90 at the start of the year. Since then, CATX shares have decreased by 16.2% and is now trading at $9.97. View the best growth stocks for 2024 here. How were Perspective Therapeutics' earnings last quarter? Perspective Therapeutics, Inc. (NYSE:CATX) posted its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.10. The firm had revenue of $0.33 million for the quarter. Perspective Therapeutics had a negative net margin of 302.70% and a negative trailing twelve-month return on equity of 46.38%. What ETF holds Perspective Therapeutics' stock? Virtus LifeSci Biotech Clinical Trials ETF holds 7,803 shares of CATX stock, representing 0.93% of its portfolio. When did Perspective Therapeutics' stock split? Perspective Therapeutics's stock reverse split on the morning of Monday, June 17th 2024. The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Perspective Therapeutics? Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CATX) was last updated on 7/1/2024 by MarketBeat.com Staff From Our Partners270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredYoung billionaire opens the door for millions of AmericansYou can now profit from a catalog of 11 inventions that will likely make their way into millions of U.S. house...Porter & Company | SponsoredBiden Replacement: The Final ChapterLast night’s debate proved me right: Joe Biden will be replaced. And how the face of America will be change...The Freeport Society | SponsoredWill Biden Be Replaced?There are growing rumors of a possible Joe Biden replacement following his first debate against Donald Trump. ...Stansberry Research | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredFed’s Plan to Control American Bank AccountsFor months I’ve been warning about the federal government’s terrifying new program to control every American’s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
